High Risk of Infection During Triple Therapy with First-Generation Protease Inhibitors: A Nationwide Cohort Study.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Gastrointestinal and Liver Diseases

• Publication date

  2016-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.15403/jgld.2014.1121.252.th3PMID 27308651
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Review article: safety and tolerability of direct‐acting anti‐viral agents in the new era of hepatitis C therapy

  2016influential reference
• Diabetes mellitus is associated with increased risk of surgical site infections: A meta-analysis of prospective cohort studies.

  2015cited by this paper
• The addition of a protease inhibitor increases the risk of infections in patients with hepatitis C-related cirrhosis.

  2015influential reference
• Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries

  2015cited by this paper
• Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET.

  2015cited by this paper
• Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease

  2015cited by this paper
• Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies

  2015cited by this paper
• Risk of infections during interferon‐based treatment in patients with chronic hepatitis C virus infection and advanced hepatic fibrosis

  2015cited by this paper
• Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis

  2015cited by this paper
• Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis.

  2015cited by this paper
• EASL Recommendations on Treatment of Hepatitis C 2015.

  2015cited by this paper
• Hepatitis C Virus Treatment Revolution: Eastern European Story

  2015cited by this paper
• Access to hepatitis C medicines

  2015cited by this paper
• A 2015 roadmap for the management of hepatitis C virus infections in Asia

  2015cited by this paper
• Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access program.

  2014cited by this paper
• Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013.

  2014cited by this paper
• Favorable adverse event profile of sofosbuvir/ribavirin compared to boceprevir/interferon/ribavirin for treatment of hepatitis C

  2014cited by this paper
• Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.

  2014influential reference
• Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort

  2014cited by this paper
• Treatment of hepatitis C: a systematic review.

  2014cited by this paper
• Cirrhosis but not neutropenia is associated with the development of infection in patients with chronic hepatitis C undergoing treatment with pegylated interferon‐alpha and ribavirin

  2014cited by this paper
• Infections during peginterferon/ribavirin therapy are associated with the magnitude of decline in absolute lymphocyte count: results of the IDEAL study.

  2014cited by this paper
• A real life boceprevir use in treatment-experienced HCV genotype 1 patients with advanced fibrosis.

  2014cited by this paper
• Overall efficacy and safety results of sofosbuvir-based therapies in phase II and III studies.

  2014cited by this paper
• Comparative Effectiveness of Antiviral Treatment for Hepatitis C Virus Infection in Adults: A Systematic Review

  2013influential reference
• Neutropenia during therapy with peginterferon and ribavirin in HIV-infected subjects with chronic hepatitis C and the risk of infections.

  2013cited by this paper
• Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.

  2013cited by this paper
• Global epidemiology of hepatitis C virus infection: New estimates of age‐specific antibody to HCV seroprevalence

  2013cited by this paper
• "Standard of care" treatment for chronic viral C hepatitis in 2013 in Romania.

  2013cited by this paper
• Treatment of hepatitis C monoinfection in adults--Dutch national guidelines.

  2013cited by this paper
• Management of bacterial infections in cirrhosis.

  2012cited by this paper
• Boceprevir for previously treated chronic HCV genotype 1 infection.

  2011cited by this paper
• Boceprevir for untreated chronic HCV genotype 1 infection.

  2011influential reference
• Risk of mortality in patients with cancer who experience febrile neutropenia

  2010cited by this paper
• Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C

  2010cited by this paper
• Bacterial infection and neutropenia during peginterferon plus ribavirin combination therapy in patients with chronic hepatitis C with and without baseline neutropenia in clinical practice

  2009cited by this paper
• Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori.

  2009cited by this paper
• Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis.

  2008cited by this paper
• Incidence of Neutropenia and Infections During Combination Treatment of Chronic Hepatitis C with Pegylated Interferon Alfa-2a or Alfa-2b Plus Ribavirin

  2008cited by this paper
• Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection

  2006cited by this paper
• Cirrhosis as a risk factor for sepsis and death: analysis of the National Hospital Discharge Survey.

  2003cited by this paper
• Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha.

  2002cited by this paper
• Risk of Mortality in Patients with End-Stage Renal Disease: The Role of Malnutrition and Possible Therapeutic Implications

  2002cited by this paper
• Innate immune response mechanisms in non-insulin dependent diabetes mellitus patients assessed by flow cytoenzymology.

  2000cited by this paper
• The evolution of the empirical management of fever and neutropenia in cancer patients.

  1998cited by this paper
• Impaired Leucocyte Functions in Diabetic Patients

  1997cited by this paper
• Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia.

  1966cited by this paper

• Direct acting antiviral therapy rescues neutrophil dysfunction and reduces hemolysis in hepatitis C infection.

  2020cites this paper
• Risk factors for thiopurine‐induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype

  2017cites this paper
• The majority of hepatitis C patients treated with direct acting antivirals are at risk for relevant drug-drug interactions

  2017cites this paper